How should recurrent axillary hidradenitis suppurativa be treated in a patient with chronic kidney disease stage 2?

Treatment of Recurrent Axillary Hidradenitis Suppurativa in CKD Stage 2

For recurrent axillary hidradenitis suppurativa in a patient with CKD stage 2, start with tetracyclines (doxycycline or minocycline) for 12 weeks as first-line therapy, escalate to clindamycin 300 mg PO twice daily plus rifampin 600 mg PO once daily for 10 weeks if inadequate response, and consider adalimumab (160 mg week 0,80 mg week 2, then 40 mg weekly) for moderate-to-severe disease refractory to antibiotics. 1

Initial Assessment and Disease Staging

Evaluate disease severity using the Physician Global Assessment (PGA) and Hurley staging. For recurrent axillary disease, you're likely dealing with at least Hurley stage II (recurrent abscesses with sinus tract formation and scarring). The CKD stage 2 (eGFR 60-89 mL/min/1.73 m²) does not significantly restrict most HS treatment options, as renal function is relatively preserved.

Stepwise Medical Management Algorithm

First-Line: Systemic Antibiotics

Tetracyclines are the recommended initial systemic therapy for mild-to-moderate HS based on the 2019 North American guidelines 1. Use doxycycline 100 mg twice daily or minocycline 100 mg twice daily for a minimum 12-week course. These are safe in CKD stage 2 without dose adjustment. Continue as long-term maintenance if effective, balancing benefit against antibiotic resistance risk.

Second-Line: Combination Antibiotic Therapy

If tetracyclines fail or for more severe disease, escalate to clindamycin 300 mg PO twice daily plus rifampin 600 mg PO once daily for 10 weeks 2, 1. This combination has Level III evidence (SOR C) but is effective as second-line treatment for mild-to-moderate disease or as first-line in severe cases. Both agents are safe in CKD stage 2.

Critical caveat: Rifampin is a potent CYP450 inducer and interacts with numerous medications. Review all concurrent medications before prescribing.

Third-Line: Biologic Therapy

For moderate-to-severe disease unresponsive to antibiotics, adalimumab is the only FDA-approved biologic for HS with Level Ib evidence (SOR A) 2, 1. Dosing: 160 mg subcutaneously at week 0,80 mg at week 2, then 40 mg weekly thereafter. Continue as long as HS lesions are present and patient responds. Adalimumab is safe in CKD stage 2 without dose adjustment.

Before initiating adalimumab:

• Screen for latent tuberculosis (IGRA or TST)
• Screen for hepatitis B and C
• Ensure no active infections
• Monitor for injection site reactions and infections during treatment

Alternative biologics with emerging evidence include infliximab (recommended for moderate-to-severe HS) 1 and secukinumab, which showed efficacy in a case report of severe HS in a dialysis patient 3. Bimekizumab (IL-17A/F inhibitor) demonstrated success in refractory HS complicated by IgA nephritis 4, though this represents cutting-edge evidence.

Adjunctive Therapies

Topical Management

• Topical clindamycin 1% may reduce pustules but carries high resistance risk 1
• Resorcinol 15% cream is recommended but may cause contact dermatitis 1
• Chlorhexidine or zinc pyrithione washes for bacterial load reduction 1

Intralesional Therapy

Intralesional triamcinolone (10-40 mg/mL) for acute inflamed nodules provides short-term flare control 1. This is particularly useful for bridging to systemic therapy or managing breakthrough lesions.

Hormonal Therapy (if female)

Consider metformin as an anti-androgen option, which is notably safe in CKD and may provide dual benefit for metabolic syndrome often comorbid with HS 5, 1. Combined oral contraceptives or spironolactone are alternatives for appropriate female patients.

Surgical Considerations

For recurrent axillary disease with sinus tracts and scarring (Hurley stage II-III), wide local excision with primary closure or flap reconstruction offers definitive treatment with low recurrence rates 6, 7, 8. Surgery should be considered:

• After medical optimization to reduce inflammation
• For localized disease with extensive scarring
• When medical therapy fails to control disease
• As part of a combined medical-surgical approach

Recent case reports demonstrate excellent outcomes with lateral thoracic fasciocutaneous flaps for axillary reconstruction 7.

CKD-Specific Considerations

Your patient's CKD stage 2 requires minimal medication adjustments but warrants attention to:

1. Avoid NSAIDs for pain management (nephrotoxic) - use acetaminophen, low-dose colchicine, or short-course oral/intralesional corticosteroids instead 9

2. Monitor cardiovascular risk: CKD patients have elevated cardiovascular disease risk. Consider statin therapy per KDIGO 2024 guidelines if age ≥50 years 10, 9

3. Infection surveillance: HS patients with ESRD show increased septicemia risk 11. While your patient has CKD stage 2, maintain heightened awareness for systemic infection signs

4. Medication safety: Most HS medications (tetracyclines, clindamycin, rifampin, adalimumab) are safe in CKD stage 2 without adjustment. Avoid dapsone if possible due to potential hemolytic anemia risk in compromised renal function

Pain Management Strategy

HS causes significant pain impacting quality of life. Avoid NSAIDs in CKD. Use:

• Acetaminophen (safe in CKD stage 2)
• Topical lidocaine for localized pain
• Short-course oral corticosteroids for acute flares (prednisone 0.5-1 mg/kg tapered over 2-4 weeks)
• Consider referral to pain management if chronic pain develops

Common Pitfalls to Avoid

1. Delaying biologic therapy: Don't cycle through multiple antibiotic regimens indefinitely. If two antibiotic courses fail, escalate to adalimumab
2. Inadequate antibiotic duration: Tetracyclines require minimum 12 weeks; shorter courses lead to relapse
3. Ignoring surgical options: Medical therapy alone often insufficient for Hurley stage II-III disease with established sinus tracts
4. Overlooking comorbidities: Screen for metabolic syndrome, diabetes, inflammatory bowel disease - all associated with HS
5. Using progestogen-only contraceptives: May worsen HS; avoid if possible 1

Monitoring Plan

• Assess response at 4-6 weeks for antibiotics, 12-16 weeks for biologics
• Monitor for antibiotic resistance and adverse effects
• Regular wound care and hygiene counseling
• Screen for depression/anxiety (highly prevalent in HS)
• Monitor renal function every 3-6 months per CKD guidelines 10